JP2018527570A - 併用療法のための患者の選択 - Google Patents

併用療法のための患者の選択 Download PDF

Info

Publication number
JP2018527570A
JP2018527570A JP2018511233A JP2018511233A JP2018527570A JP 2018527570 A JP2018527570 A JP 2018527570A JP 2018511233 A JP2018511233 A JP 2018511233A JP 2018511233 A JP2018511233 A JP 2018511233A JP 2018527570 A JP2018527570 A JP 2018527570A
Authority
JP
Japan
Prior art keywords
cells
peripheral blood
cancer
hla
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018511233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527570A5 (OSRAM
Inventor
ピーター オルデントリッヒ，
ピーター オルデントリッヒ，
Original Assignee
シンダックス ファーマシューティカルズ，インク．
シンダックス ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンダックス ファーマシューティカルズ，インク．, シンダックス ファーマシューティカルズ，インク． filed Critical シンダックス ファーマシューティカルズ，インク．
Publication of JP2018527570A publication Critical patent/JP2018527570A/ja
Publication of JP2018527570A5 publication Critical patent/JP2018527570A5/ja
Priority to JP2021173852A priority Critical patent/JP7206352B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2018511233A 2015-09-02 2016-09-02 併用療法のための患者の選択 Withdrawn JP2018527570A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021173852A JP7206352B2 (ja) 2015-09-02 2021-10-25 併用療法のための患者の選択

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562213288P 2015-09-02 2015-09-02
US62/213,288 2015-09-02
US201562219612P 2015-09-16 2015-09-16
US62/219,612 2015-09-16
PCT/US2016/050274 WO2017041043A1 (en) 2015-09-02 2016-09-02 Selection of patients for combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021173852A Division JP7206352B2 (ja) 2015-09-02 2021-10-25 併用療法のための患者の選択

Publications (2)

Publication Number Publication Date
JP2018527570A true JP2018527570A (ja) 2018-09-20
JP2018527570A5 JP2018527570A5 (OSRAM) 2019-12-12

Family

ID=58188549

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018511233A Withdrawn JP2018527570A (ja) 2015-09-02 2016-09-02 併用療法のための患者の選択
JP2021173852A Active JP7206352B2 (ja) 2015-09-02 2021-10-25 併用療法のための患者の選択

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021173852A Active JP7206352B2 (ja) 2015-09-02 2021-10-25 併用療法のための患者の選択

Country Status (14)

Country Link
US (2) US11397184B2 (OSRAM)
EP (1) EP3345002A4 (OSRAM)
JP (2) JP2018527570A (OSRAM)
KR (2) KR102631377B1 (OSRAM)
CN (2) CN108139403B (OSRAM)
AU (2) AU2016318136B2 (OSRAM)
BR (1) BR112018003238A2 (OSRAM)
CA (1) CA2994731C (OSRAM)
HK (1) HK1258128A1 (OSRAM)
IL (1) IL257355B (OSRAM)
MX (1) MX2018002640A (OSRAM)
RU (1) RU2018111407A (OSRAM)
WO (1) WO2017041043A1 (OSRAM)
ZA (1) ZA201800931B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508593A (ja) * 2015-03-20 2018-03-29 シンダックス ファーマシューティカルズ，インコーポレイティド がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ
RU2018130831A (ru) 2016-01-28 2020-03-02 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Применение ингибиторов деацетилаз гистонов для улучшения иммунотерапии
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP7373991B2 (ja) 2016-07-15 2023-11-06 ビラクタ セラピューティクス，インク． 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
EP3624848A1 (en) 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Combination therapies
AU2019266231B2 (en) * 2018-05-07 2025-08-21 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
CN109251891B (zh) * 2018-09-21 2021-10-22 苏州大学附属第一医院 一种cd40联合pd-l1及细胞因子扩增pbmc的方法
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033656A1 (en) * 2011-09-02 2013-03-07 Syndax Pharmaceuticals, Inc. Methods for the treatment of breast cancer
WO2014085461A1 (en) * 2012-11-29 2014-06-05 The Penn State Research Foundation Photodynamic dhsip anticancer therapeutic and immunomodulator
WO2016010879A1 (en) * 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
ITUD20080058A1 (it) * 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
GB201015765D0 (en) * 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
EP3682896A1 (en) * 2011-04-28 2020-07-22 University of Southern California Human myeloid derived suppressor cell cancer markers
EP2872125A4 (en) * 2012-07-10 2016-02-24 Dana Farber Cancer Inst Inc ANTIPROLIFERATIVE COMPOUNDS AND USES THEREOF
JP2018508593A (ja) * 2015-03-20 2018-03-29 シンダックス ファーマシューティカルズ，インコーポレイティド がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ−１抗体の組合せ

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033656A1 (en) * 2011-09-02 2013-03-07 Syndax Pharmaceuticals, Inc. Methods for the treatment of breast cancer
WO2014085461A1 (en) * 2012-11-29 2014-06-05 The Penn State Research Foundation Photodynamic dhsip anticancer therapeutic and immunomodulator
WO2016010879A1 (en) * 2014-07-15 2016-01-21 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELENI-KYRIAKI VETSIKA, ET AL: "A circulating subpopulatin of monocitic myeloid-derived suppressor cells as an independent prognosti", JOURNAL OF IMMUNOLOGY RESEARCH, vol. vol.2014, article ID 659294, JPN6020031042, 2014, pages 1 - 12, ISSN: 0004534241 *
KIBEM KIM, ET AL.: "Eradication of metastatic mouse cancers resistant to immune checkpoint blockaged by suppression of m", PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 111, no. 32, JPN6020031041, 2014, pages 11774 - 11779, ISSN: 0004534240 *

Also Published As

Publication number Publication date
AU2016318136B2 (en) 2022-10-20
CA2994731C (en) 2023-09-26
ZA201800931B (en) 2023-12-20
US20230061048A1 (en) 2023-03-02
JP7206352B2 (ja) 2023-01-17
KR20180048703A (ko) 2018-05-10
BR112018003238A2 (en) 2018-09-25
IL257355A (en) 2018-04-30
WO2017041043A1 (en) 2017-03-09
CN108139403B (zh) 2023-05-09
AU2022246409A1 (en) 2022-11-03
MX2018002640A (es) 2018-06-20
RU2018111407A (ru) 2019-10-03
CN116893262A (zh) 2023-10-17
CN108139403A (zh) 2018-06-08
CA2994731A1 (en) 2017-03-09
EP3345002A1 (en) 2018-07-11
US11397184B2 (en) 2022-07-26
RU2018111407A3 (OSRAM) 2020-02-10
IL257355B (en) 2021-10-31
KR102631377B1 (ko) 2024-01-29
KR20240017973A (ko) 2024-02-08
US20180252721A1 (en) 2018-09-06
JP2022009460A (ja) 2022-01-14
HK1258128A1 (zh) 2019-11-08
EP3345002A4 (en) 2019-05-08
AU2016318136A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
JP7206352B2 (ja) 併用療法のための患者の選択
JP7540980B2 (ja) がんを処置するためのｈｄａｃ阻害剤および抗ｐｄ－１抗体の組合せ
Santana-Krímskaya et al. IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model
JP2019518741A (ja) Ｈｄａｃ阻害剤とｐｄ−ｌ１阻害剤との組み合わせ療法
JP2025179057A (ja) 併用療法のための患者の選択
HK40096805A (zh) 用於组合疗法的患者的选择
HK40050163A (en) Selection of patients for combination therapy
HK40050163B (en) Selection of patients for combination therapy
HK1250142B (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer wherein the combination does not comprise 5-azacytidine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191029

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211025

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220104

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220105

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220112